Home › T-Cell Lymphoma › Maryland › Baltimore
T-Cell Lymphoma clinical trials in Baltimore, MD
4 studies for T-Cell Lymphoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
- University of Maryland/Greenebaum Cancer Center, Baltimore
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- University of Maryland Medical Center, Baltimore
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Johns Hopkins University, Baltimore
T-Cell Lymphoma trials in other cities
- New York City, NY13 studies
- Philadelphia, PA10 studies
- Baldwin Park, CA9 studies
- Boston, MA9 studies
- Houston, TX8 studies
- Atlanta, GA8 studies
- Chicago, IL6 studies
- Seattle, WA6 studies
- Columbus, OH6 studies
- Rochester, MN6 studies
- Miami, FL5 studies
- New Haven, CT5 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.